| Q44102725 | A cautionary note on experimental artefacts induced by fetal calf serum in a viral model of pulmonary eosinophilia |
| Q36082419 | Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine |
| Q36404256 | Antigen-dependent and -independent Ca2+ responses triggered in T cells by dendritic cells compared with B cells |
| Q57895751 | Augmentation of immune response by an analog of the antigenic peptide in a human T-cell clone recognizing mutated Ras-derived peptides |
| Q34959906 | Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients |
| Q35171011 | CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion |
| Q37773276 | Cancer immunotherapy by fusions of dendritic cells and tumor cells |
| Q37259630 | Cell fusion: from hybridoma to dendritic cell-based vaccine. |
| Q40916271 | Chronic myeloid leukemia as an immunological target |
| Q36644294 | Cimetidine modulates the antigen presenting capacity of dendritic cells from colorectal cancer patients |
| Q41720736 | Colorectal cancer vaccines |
| Q36490771 | Combinatorial cancer immunotherapy |
| Q40748647 | Comparison of anti-tumor responses against TL positive lymphoma induced by skin grafting and dendritic cell immunization |
| Q50335818 | Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. |
| Q41495234 | Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens |
| Q57598880 | Cytolytic T-cell responses to human dendritic cells and macrophages infected with Mycobacterium bovis BCG and recombinant BCG secreting listeriolysin |
| Q77326184 | DC-based cancer immunotherapy: the sequel |
| Q36377402 | Dendritic cell development in culture from thymic precursor cells in the absence of granulocyte/macrophage colony-stimulating factor |
| Q35775188 | Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives |
| Q34216506 | Dendritic cells and immunotherapy for malignant disease |
| Q41649620 | Dendritic cells as adjuvants for immune-mediated resistance to tumors |
| Q36380749 | Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity |
| Q43811691 | Dendritic cells hold promise for immunotherapy |
| Q36404280 | Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue |
| Q36924579 | Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro |
| Q73046078 | Dendritic cells need T cell help to prime cytotoxic T cell responses to strong antigens |
| Q35079386 | Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells |
| Q40699456 | Dendritic cells: On the move from bench to bedside |
| Q33579423 | Dendritic cells: therapeutic potentials |
| Q36367631 | Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified |
| Q43983069 | Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells |
| Q45875131 | Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines |
| Q40753335 | Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells |
| Q35005930 | Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens |
| Q73922532 | Expression of MHC and adhesion/costimulation molecules of dendritic cells from human blood during their differentiation in vitro |
| Q78028306 | Expression of surface antigens during the differentiation of human dendritic cells vs macrophages from blood monocytes in vitro |
| Q73221913 | Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine |
| Q73400017 | Flt3 ligand induces tumor regression and antitumor immune responses in vivo |
| Q37999967 | From genes to drugs: targeted strategies for melanoma |
| Q77608031 | Fully mobilizing host defense: building better vaccines |
| Q36166960 | GM-CSF gene-transduced tumor vaccines |
| Q35005952 | GM-CSF-based cancer vaccines |
| Q35146599 | GM-CSF-secreting melanoma vaccines |
| Q33536357 | Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application |
| Q73878119 | Generation of monocyte-derived dendritic cells from precursors in rhesus macaque blood |
| Q40885233 | Generation of peptide-specific cytotoxic T lymphocytes using allogeneic dendritic cells capable of lysing human pancreatic cancer cells |
| Q77362612 | Generation of stable monocyte-derived dendritic cells in the presence of high concentrations of homologous or autologous serum: influence of extra-cellular pH |
| Q41433309 | Granulocyte-macrophage colony-stimulating factor and the immune system |
| Q37823518 | Guiding the "misguided" - functional conditioning of dendritic cells for the DC-based immunotherapy against tumours |
| Q40243960 | HBV genes induce cytotoxic T-lymphocyte response upon adeno-associated virus (AAV) vector delivery into dendritic cells |
| Q45862575 | Human PBMC-derived dendritic cells transduced with an adenovirus vectorinduce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro. |
| Q36375450 | Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) |
| Q40896381 | Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines |
| Q40806767 | Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas |
| Q34898366 | Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines. |
| Q34374572 | Immunologic self tolerance maintained by T-cell-mediated control of self-reactive T cells: implications for autoimmunity and tumor immunity |
| Q41701856 | Immunological ignorance of silent antigens as an explanation of tumor evasion |
| Q41349081 | Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions |
| Q53922274 | In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells. |
| Q37382571 | In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma |
| Q34792069 | Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells |
| Q77675938 | Induction of antigen presentation by macrophages after phagocytosis of tumour apoptotic cells |
| Q73321311 | Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells |
| Q61623420 | Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations |
| Q33815011 | Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer |
| Q37352655 | Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer |
| Q37520229 | Inflammation and TCR signal strength determine the breadth of the T cell response in a bim-dependent manner. |
| Q34074814 | Influence of photodynamic therapy on immunological aspects of disease - an update |
| Q34182039 | Innovations and strategies for the development of anticancer vaccines |
| Q61762182 | Les cellules dendritiques: un système cellulaire complexe |
| Q34980036 | Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts |
| Q36181145 | Mechanisms of action of DNA vaccines |
| Q48828315 | Modified immunoregulation associated with interferon-gamma treatment of rat glioma |
| Q37592383 | Novel adjuvants & delivery vehicles for vaccines development: a road ahead |
| Q34734131 | Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer |
| Q39265240 | Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity |
| Q34075717 | Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients |
| Q40906220 | Origin, maturation and antigen presenting function of dendritic cells. |
| Q37153638 | Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis |
| Q40823586 | Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen |
| Q51792057 | Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. |
| Q40850940 | Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function |
| Q43747186 | Pre-clinical evaluation of an in vitro selection protocol for the enrichment of transduced CD34+ cell-derived human dendritic cells. |
| Q40559621 | Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine |
| Q35784239 | Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus |
| Q33588526 | Prospects for the therapeutic use of anticancer vaccines |
| Q41038497 | Protection of mice against SV40 tumours by Pam3Cys, MTP-PE and Pam3Cys conjugated with the SV40 T antigen-derived peptide, K(698)-T(708). |
| Q36944377 | Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells |
| Q45734168 | Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector |
| Q40819560 | Recognition of chronic myelogenous leukaemia cells by autologous T lymphocytes primed in vitro against the patient's dendritic cells |
| Q37806963 | Regulation of tumor immunity by tumor/dendritic cell fusions |
| Q40632606 | Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells. |
| Q37396123 | Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells |
| Q38102815 | Role of MHC class Ib molecule, H2-M3 in host immunity against tuberculosis |
| Q34801021 | Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization |
| Q41921184 | Surface expression of HLA-DM on dendritic cells derived from CD34-positive bone marrow haematopoietic stem cells |
| Q34452071 | T-cell-directed cancer vaccines: the melanoma model |
| Q36380989 | TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor |
| Q57240725 | The Labyrinthine Ways of Cancer Immunotherapy–T Cell, Tumor Cell Encounter: “How Do I Lose Thee? Let Me Count the Ways” |
| Q83177178 | The contribution of dendritic cells to immune responses against urological cancers |
| Q48049094 | The defined attenuated Listeria monocytogenes delta mp12 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma |
| Q35946203 | The new vaccines: building viruses that elicit antitumor immunity. |
| Q64381308 | Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells |
| Q36438078 | Tumor antigens discovery: perspectives for cancer therapy |
| Q40415241 | Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma |
| Q35214398 | Tumor-associated antigens: from discovery to immunity |
| Q47901582 | Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sézary syndrome: its enhancement by interferon-gamma (IFN-gamma) and IL-12 and fluctuations in association with disease activity |
| Q40487777 | Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells |
| Q36367022 | Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes |
| Q36198632 | Vaccines in cancer: GVAX, a GM-CSF gene vaccine |
| Q43981596 | Whole virus influenza vaccine activates dendritic cells (DC) and stimulates cytokine production by peripheral blood mononuclear cells (PBMC) while subunit vaccines support T cell proliferation. |
| Q33544032 | Why are dendritic cells central to cancer immunotherapy? |